Sun Pharma to conduct clinical trial in COVID-19 patients

Friday, 29 May 2020Newsdesk

Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

New Delhi, 29 May 2020

"Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany," the company said in a statement. As per news report of Reuters, The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.

Source -in.reuters.com